CDI Labs Launches Technology Access Program for Custom PhIP-Seq Libraries for Massively Multiplexed Analysis of Serum Antibodies

New Custom Offering Expands Researcher Access to CDI Labs' Phage Display Immunoprecipitation Sequencing (PhIP-Seq) Services for High-throughput Seromic Analysis

TORONTO, March 27, 2025 /PRNewswire/ -- CDI Labs Canada Inc., a leading provider of services for proteome-wide antibody profiling and target identification, today announced the launch of its Technology Access Program for custom peptide libraries for serum antibody analysis services. These services utilize phage display immunoprecipitation sequencing (PhIP-Seq), a powerful method of multiplexed analysis that combines next-generation proteomics with high-throughput DNA sequencing, to provide researchers with unparalleled insights into the intricate connection between antibodies and diseases. This new capability allows scientists to conduct epitope-level antibody discovery and profiling using a peptide library designed for their specific research needs.

"CDI Labs is dedicated to offering researchers cutting-edge and highly flexible services to unlock the crucial insights hidden in serum antibodies, paving the way for a deeper understanding of human diseases and conditions," said Barney Saunders, PhD, CEO of CDI Labs. "Our customized PhIP-Seq libraries address the growing need for tailored solutions in the rapidly advancing field of high-throughput serology. Researchers can now conduct epitope-level antibody discovery and profiling with libraries specifically designed for their unique requirements, enhancing efficiency and expanding the technology's accessibility and relevance to a broader scientific community."

Custom PhIP-Seq libraries expand the existing portfolio of PhIP-Seq services currently offered by CDI Labs Canada, which include HuScan® and MouseScan™ services which analyze samples (serum, plasma, CSF, etc.) for the presence of autoantibodies against a full RefSeq human or mouse proteome in a single-well assay with quantitative sequencing readouts.

VirScan®, HuScan and MouseScan PhIP-seq services are offered exclusively through CDI Labs Canada which is based in Toronto, Ontario.

About CDI Laboratories, Inc.

CDI Labs is a specialized CRO and lab services proteomics company. Powered by cutting-edge synthetic biology platforms, CDI Labs has generated the world's largest collection of proteomes, and in doing so has built a team with deep proteomics bench expertise. CDI Labs offers unique services that enable customers to decipher and characterize molecular interactions across entire proteomes. Solutions span basic research, discovery, validation and clinical deployment phases, and include: autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream validation. To learn more about the latest services and technologies offered by CDI Labs, please visit our website at cdilabs.com.

VirScan and HuScan are registered trademarks, and MouseScan is a trademark of CDI Laboratories, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

CDI Labs Canada

MaRS Centre - West Tower 
661 University Ave
Suite 1300 
Toronto, ON
CANADA M5G 0B7

Tel: +1 647-243-5289
Email: [email protected]

Media Contact
Chris Grimley
+1 415-425-8864
[email protected]

© 2025 CDI Labs Canada. All rights reserved.

SOURCE CDI LABORATORIES, INC.